CEO of Major U.S. Diagnostics Firm Sells Shares Worth Billions While Securing New Term Loan

Adam H. Schechter, CEO of U.S. diagnostics company Labcorp Holdings Inc. (NYSE: LH), sold 8,705 shares of the company’s common stock at approximately $279.96 per share on March 3, generating about $2.44 million (roughly KRW 3.6 billion) in cash. After the transaction, Schechter still holds 80,773 shares, representing some $22.7 million (approximately KRW 33.4 billion) at current market prices. On March 20, the parent company and borrower, Laboratory Corporation of America Holdings, entered into a term‐loan credit agreement with Wells Fargo and a lending syndicate, establishing a new long‐term debt structure.

On January 14, Labcorp declared a quarterly cash dividend of $0.72 per common share, which was paid to shareholders on March 12, continuing its program of regular shareholder returns. Then on February 17, the company reported its fourth‐quarter and full‐year 2025 financial results, issued guidance for 2026, and reaffirmed its strategies to expand partnerships with health systems and regional laboratories as well as to broaden its specialty testing services.

Headquartered in Burlington, North Carolina, Labcorp is a global provider of diagnostics testing and drug‐development services, performing over 700 million tests annually across about 100 countries for hospitals, pharmaceutical companies, and research institutions. In 2024, the company changed its name from Laboratory Corporation of America Holdings to Labcorp Holdings Inc. and now operates under two core segments: diagnostics testing and biopharma research support.